DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20183511

Role of Saccharomyces boulardii and Bacillus clausii in reducing the duration of diarrhea: a three-armed randomised controlled trial

Vidjeadevan D., Vinoth S., Ramesh S.

Abstract


Background: Diarrhea is a major public health problem. Probiotics have been recommended as an add-on therapy for the treatment of diarrhea. Recently Saccharomyces boulardii and Bacillus clausii, yeast and spore forming bacilli are among the probiotics in use for diarrheal disorder.

Methods: This was a three armed randomised controlled trial conducted in pediatrics department, in a tertiary level care at Chidambaram. The randomisation was done using permuted blocks method. Of the three groups, Group A received ORS and zinc; Group B ORS, zinc and S. boulardii and Group C ORS, zinc and B. clausii. The outcome variables included duration of diarrhea and duration of stay in hospital.

Results: The duration of diarrhea decreased significantly in Group B and C than Group A. Both the probiotics had similar effect in reducing the duration of diarrhea. There was no significant difference in duration of stay at hospital between the groups.

Conclusions: Addition of probiotics as an add-on therapy would aid in decreasing the duration of diarrhea rather than giving ORS and zinc alone. The duration of stay in hospital was unaffected by the change in regimen of treatment.


Keywords


B. clausii, Probiotics, S. boulardii, Three armed randomised controlled trial

Full Text:

PDF

References


Factsheet. Diarrheal disease. WHO media centre. 2017. Available at: http://www.who.int/mediacentre/factsheets/fs330/en/

Million Death Study Collaborators. Causes of neonatal and child mortality in India: a nationally representative mortality survey. The Lancet. 2010 Nov 27;376(9755):1853-60.

Walker CL, Perin J, Aryee MJ, Boschi-Pinto C, Black RE. Diarrhea incidence in low-and middle-income countries in 1990 and 2010: a systematic review. BMC Public Health. 2012 Dec;12(1):220.

Hoque K, Binder H. Zinc in the treatment of acute diarrhea: current status and assessment. Gastroenterol. 2006;130(7):2201-5.

Pelletier DL, Frongillo EA, Habicht JP. Clinical management of acute diarrhea acute diarrhea still a leading cause of child deaths’ epidemiologic evidence for a potentiating effect of malnutrition on child mortality. Am J Public Health. 1993;83(8):1130-3.

Jayanthi N, Sudha RM. Bacillus clausii-The Probiotic of Choice in the Treatment of Diarrhoea. J Yoga Physical Therapy. 2015 Oct 1;5(4):1.

Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010 Jan 1;11(11).

Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Jama. 2012 May 9;307(18):1959-69.

Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007 Aug 16;335(7615):340.

Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009;168(3):253-65.

Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1):e176-91.

Vineeth S, Saireddy S, Keerthi T, Mantada PK. Efficacy of Bacillus clausii and Saccharomyces boulardii in treatment of acute rotaviral diarrhea in pediatric patients. Indonesian J Clinical Pharmacy. 2017 Jun 1;6(2):91-8.